Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Factors Influencing Drug Absorption: Drug Dissolution

Factors Influencing Drug Absorption: Drug Dissolution

The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Digitized Health Opens RWE Floodgates. Can Artificial Intelligence Harness the Power?

Managed care (Langhorne, Pa.)·2019

Same authorSame journal

To Be Continued:The Search for a Cure for HIV.

Managed care (Langhorne, Pa.)·2019

Same author

Show Us (the U.S.) the Savings.

Managed care (Langhorne, Pa.)·2019

Same author

Why Biosimilars Can Never Be Identical To Originators-and Why They Don't Need To Be.

Managed care (Langhorne, Pa.)·2019

Same author

Why marijuana is headed for the mainstream.

Managed care (Langhorne, Pa.)·2019

Same author

Dupixent, a New Entrant In the Asthma Lists.

Managed care (Langhorne, Pa.)·2018

Search research articles

Related Experiment Video

Updated: Feb 4, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Rumble Over Drug Rebates As Pharma, Payers Duke It Out.

Managed Care (Langhorne, Pa.)

|October 13, 2018

Summary

Pharmaceutical companies claim rebates drive up drug prices. Pharmacy Benefit Managers (PBMs) and payers argue these rebates reduce costs for health plans and patients through lower premiums and copays.

Area of Science:

Health Economics
Pharmaceutical Policy
Market Dynamics

Background:

The pharmaceutical industry and Pharmacy Benefit Managers (PBMs) present conflicting views on the impact of drug rebates on drug pricing.
The core of the dispute lies in whether rebates increase or decrease overall healthcare costs for consumers.

Purpose of the Study:

To analyze the stated positions of pharmaceutical manufacturers and PBMs/payers regarding the role of rebates in drug pricing.
To investigate the economic arguments presented by each party concerning the pass-through of rebates to consumers.

Main Methods:

Review of industry statements and economic analyses from pharmaceutical manufacturers.
Examination of PBM and payer reports and counterarguments on rebate utilization and consumer savings.

Keywords:

Drug Benefit Plans Drug Costs Economics, Pharmaceutical Insurance, Pharmaceutical Services Medication Management

More Related Videos

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Related Experiment Videos

Last Updated: Feb 4, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Main Results:

Pharmaceutical manufacturers assert that rebate demands by payers lead to higher list prices for drugs.
PBMs and payers contend that rebates are substantially passed on, resulting in significant consumer savings via reduced premiums and copayments.

Conclusions:

The differing perspectives highlight a complex interplay between drug pricing, rebate negotiations, and consumer cost-sharing.
Further investigation is needed to definitively quantify the net effect of rebates on drug prices and patient affordability.